EGFR and breast carcinoma: In this work, antibody-guided ANANAS were evaluated and quantitatively compared with direct ADCs for targeted drug delivery in breast cancer therapy using an anti-epidermal growth factor receptor (EGFR) antibody (cetuximab) as the targeting element and doxorubicin as the cytotoxic compound.